Your browser does not support SVG.
Board of Directors
April 3, 2018
Dermavant Expands Pipeline and Strengthens Executi ...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
Dermavant Sciences to Present Data on Tapinarof for Psoriasis and Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting